Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AFLAC Incorporated (AFL) vs Alexandria Real Estate Equities Inc (ARE) Price & Performance

AFLAC Incorporated
Alexandria Real Estate Equities Inc

Price performance

Price movement over the last 24 hours

Key statistics

AFLAC Incorporated vs Alexandria Real Estate Equities Inc — how do they compare? AFLAC Incorporated trades at $121.41 (market cap $61.84B), while Alexandria Real Estate Equities Inc trades at $48.04 (market cap $8.61B). The key difference: AFLAC Incorporated is far larger — about 7.2× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (5.83%). Which is the better fit depends on your goals.

AFLARE
Market Cap
$61.84B$8.61B
Sector
FinancialsReal Estate
52-Week High
$121.49$87.45
52-Week Low
$98.09$40.41
Enterprise Value
$70.50B$21.07B
Dividend Yield
2.01%5.83%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AFLAC Incorporated

Aflac (AFL) trades at $121.49, up 0.5% with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 25.32% net income margin and 16.47% ROE, though recent Q1 2026 earnings missed expectations. Analyst consensus is mixed with 28% buy ratings and a $113.57 price target below current levels. Recent developments include strong dividend performance and upcoming Q2 2026 results announcement on August 6, 2026.

The outlook remains cautiously optimistic with solid profitability and dividend stability, but faces headwinds from recent earnings misses and premium valuation pressure. Key opportunities include continued growth in Japan and U.S. markets, while risks involve medical cost inflation and uneven revenue trends. The stock's current premium to analyst targets suggests limited near-term upside potential.

Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities (ARE) trades at $49.41, down 6.03% over 24 hours amid bearish technical signals and mixed fundamentals. The stock shows negative profitability with -37.09% net income margin and -6.43% ROE, though valuation metrics like P/B of 0.55 suggest potential undervaluation. Recent earnings have been inconsistent with two misses in the last four quarters. The company maintains strong operational cash flow of $1.41B and declared a $0.72 dividend for Q2 2026.

ARE faces headwinds from declining occupancy guidance and net losses, but analyst consensus remains cautiously optimistic with a $51 price target and 37.5% buy ratings. Key risks include high debt levels (40.79% debt-to-asset ratio) and uneven demand in life science real estate. The stock's current position near support at $49 offers potential for recovery if operational improvements materialize.

Returns comparison

Trailing returns across standard periods

About AFLAC Incorporated

Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.

Read more on AFL

About Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.

Read more on ARE